Stock On the Run: Sage Therapeutics, Inc. (SAGE)

14

Sage Therapeutics, Inc. (SAGE) belonging to the Healthcare sector has surged 19.62% and closed its last trading session at $175.76.
The company reported its EPS on 3/30/2018. Currently, the stock has a 1 Year Price Target of $206.79.
The consensus recommendation, according to Zacks Investment research, is 1.04. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.13 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.13 and 1.13 respectively.
Sage Therapeutics, Inc. on 3/30/2018 reported its EPS as $-1.88 with the analysts projecting the EPS of the stock as $-1.67. The company beat the analyst EPS Estimate with the difference of $-0.21. This shows a surprise factor of -0.126%.
Many analysts have provided their estimated foresights on Sage Therapeutics, Inc. Earnings, with 12 analysts believing the company would generate an Average Estimate of $-1.88.
Whereas they predicted High and Low Earnings Estimate as $-1.73 and $-2.06 respectively. While in the same Quarter Previous year, the Actual EPS was $-1.88.
Sage Therapeutics, Inc. (SAGE) has the market capitalization of $8.47 Billion. The company rocked its 52-Week High of $195.97 and touched its 52-Week Low of $59.57.
The stock has Return on Assets (ROA) of -53 percent. Return on Equity (ROE) stands at -57.7% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 6.71 Percent. The company has Beta Value of 3 and ATR value of 8.31. The Weekly and Monthly Volatility stands at 6.40% and 5.03%.